ClinicalTrials.Veeva

Menu

Evaluation of Preexisting Immunity Markers in Human Tumor Tissue Sample

Stanford University logo

Stanford University

Status

Completed

Conditions

Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT00568867
SU-11072007-830
VAR0018 (Other Identifier)
97310 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to evaluate markers of immune response in human tumor samples.

Full description

Cancer immunotherapy has been shown to be effective in isolated instances, but ineffective in most patients. The reason for this inconsistency, and the conditions necessary for successful immunotherapy, are not well understood. Our studies in animal tumor models indicate that the effectiveness of IL-12-based immunotherapy depends upon the presence of a preexisting immune response to the tumor. The presence of T cell infiltrates and IFN-gamma expression in tumor indicate such an immune response. We therefore plan to evaluate the existing immune response in human tumor samples in an effort to identify those patients most likely to respond to therapy with IL-12.

Enrollment

300 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:Any adult patient with a tumor who is scheduled to undergo surgery to either remove or biopsy the tumor. Exclusion Criteria:Patients without tumor and pediatric patients (children) will be excluded.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems